Tag: action

SAN DIEGO, July 09, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that the XPLR Infrastructure class action lawsuit seeks to represent purchasers or acquirers of XPLR Infrastructure, LP f/k/a NextEra Energy Partners, LP (NYSE: XIFR) securities between September 27, 2023 and January 27, 2025, inclusive (the “Class Period”). Captioned Alvrus v. XPLR Infrastructure, LP f/k/a NextEra Energy Partners, LP, No. 25-cv-01755 (S.D. Cal.), the XPLR Infrastructure class action lawsuit charges XPLR Infrastructure, NextEra Energy, Inc., and certain of XPLR Infrastructure’s top former executives with violations of the Securities Exchange Act of 1934.

Investors can contact the law firm at no cost to learn more about recovering their losses

Investors can contact the law firm at no cost to learn more about recovering their losses

NEW YORK, July 09, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Sable Offshore Corp. (NYSE: SOC), including those who purchased shares pursuant to Sable Offshore Corp.’s May 2025 public offering, resulting from allegations that Sable Offshore Corp. may have issued materially misleading business information to the investing public.

NEW YORK, July 09, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) between May 9, 2024 and May 8, 2025, both dates inclusive (the “Class Period”), of the important July 14, 2025 lead plaintiff deadline.

Daix (France), New York City (New York, United States), July 9, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced a leadership transition with the appointment of Jason Campagna, MD, PhD, as President of Research and Development (“R&D”) and Chief Medical Officer (“CMO”) and Martine Zimmermann, PharmD, as Executive Vice President (“EVP”) of Regulatory Affairs and Quality Assurance.

Nombre total de droits de vote et d’actions composant le capital en date du 30 juin 2025
(Art. L. 233-8 (II) du Code de Commerce et Art. 223-16 du Règlement Général de l’AMF)

NEW YORK, July 09, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: